JPMorgan initiated coverage of Enanta with an Overweight rating and $17 price target. The firm cites the recent Phase 2b data for zelicapavir in respiratory syncytial virus for the positive view. The viral infection has significant unmet need and the study showed faster symptom reduction in the overall population, the analyst tells investors in a research note.
